Business Context and Reporting Period
iBio, Inc. is a biotechnology company commercializing plant-based biologics platforms: iBioLaunch for vaccines and therapeutic proteins and iBioModulator for enhancing vaccine potency and duration. The filing is a Form 10-K for the fiscal year ended June 30, 2013, filed September 30, 2013. The requested “2012 Q4” period does not match the filing’s annual reporting period.
The company had no approved or commercialized products. Its pipeline was principally preclinical, except for completed Phase 1 studies of H1N1 and H5N1 influenza vaccine candidates. Near-term strategy focused on licensing, collaborations and advancing selected candidates, including recombinant C1 esterase inhibitor.
Financial Results and Liquidity
| Metric | FY2013 | FY2012 | Change |
|---|---|---|---|
| Revenue | $1.007 million | $1.277 million | Down $0.270 million |
| Research and development expense | $3.431 million | $4.981 million | Down $1.550 million |
| General and administrative expense | $4.243 million | $5.623 million | Down $1.380 million |
| Operating loss | $6.667 million | $9.327 million | Improved $2.660 million |
| Net loss | $6.198 million | $5.676 million | Worsened $0.522 million |
| Basic and diluted loss per share | $0.13 loss | $0.14 loss | Improved per share |
| Net cash used in operating activities | $4.849 million | $6.010 million | Improved $1.161 million |
| Net cash provided by financing activities | $3.834 million | $9.036 million | Down $5.202 million |
| Cash at year-end | $4.414 million | $5.624 million | Down $1.210 million |
Revenue consisted of research and development services provided to FioCruz through Fraunhofer for a planned yellow fever vaccine program. No license revenue was recorded in either year. Approximate operating margin was negative 662% in FY2013, compared with negative 730% in FY2012; approximate net margin was negative 615% versus negative 445%.
At June 30, 2013, total assets were $9.354 million, current assets were $6.635 million, total liabilities were $4.286 million and stockholders’ equity was $5.068 million. The filing does not identify conventional funded debt; liabilities primarily consisted of accounts payable and accrued expenses. Intangible assets were $2.713 million.
Management expected $4.4 million of cash on hand, after considering the September 2013 Fraunhofer settlement, to fund operations through the third quarter of fiscal 2014. The company stated that substantial additional financing would be required and disclosed substantial doubt about its ability to continue as a going concern. No committed external funding source existed.
Material Changes Versus the Prior Comparable Period
- Revenue declined approximately 21% because the company performed less FioCruz-related research and development work.
- Research and development expense declined 31%, primarily because two large Fraunhofer projects were completed in FY2012 and no comparable projects were undertaken in FY2013.
- General and administrative expense declined 25%, largely because of lower share-based compensation and the absence of the prior-year option modification charge.
- Net loss increased despite lower operating expenses because FY2012 included approximately $3.668 million of non-cash income from the change in fair value of the warrant derivative liability, compared with $0.520 million in FY2013.
- Cash used in operations improved, but financing proceeds fell substantially year over year, leaving year-end cash lower.
- Shares outstanding increased from approximately 47.8 million to 56.7 million, primarily due to the April 2013 equity offering.
Guidance, Outlook, Risks and Unusual Items
- On April 26, 2013, iBio raised approximately $3.8 million net through the issuance of 8.925 million shares and warrants for up to 3.57 million shares. The warrants had a $0.53 exercise price and expire in April 2016.
- In September 2013, iBio and Fraunhofer settled their technology transfer agreement. Approximately $2.9 million of liabilities were released, the scheduled $3.0 million of cash payments were replaced by a commitment to purchase at least $3.0 million of directed research and development services through December 31, 2015, and minimum annual royalty payments were eliminated.
- The settlement reduced the royalty rate on iBio platform license revenue from 15% to 10% and is expected to produce an approximately $1.9 million positive earnings impact in the quarter ended September 30, 2013. Approximately $1.8 million of the new research commitment had already been allocated to C1 esterase inhibitor and FioCruz technology-transfer work.
- Approximately 5 million August 2008 warrants expired unexercised in August 2013. The warrant derivative liability was zero at June 30, 2013.
- FioCruz committed to the design of a plant-based multipurpose manufacturing facility in Brazil with GE Healthcare. Construction was anticipated in the following years, but no commercial revenue was assured.
- Management expected continued losses and did not provide revenue, earnings or product approval guidance. Commercial revenues, if any, were expected primarily from development fees, milestones, licenses and royalties, potentially several years in the future.
- Key risks include dependence on additional equity financing and collaborators, early-stage product development, regulatory and clinical failure, competition, intellectual-property challenges, dilution, and limited operating history.
- The company received NYSE MKT notices concerning stockholders’ equity, losses and financial condition, with an extension to regain compliance through October 14, 2013. Failure to regain compliance could have resulted in delisting.
Most Important Facts for Investors to Verify
- Verify the going-concern conclusion, available cash and actual financing obtained after June 30, 2013.
- Verify the accounting and cash-flow effects of the September 2013 Fraunhofer settlement, including the $2.9 million liability release and $3.0 million research commitment.
- Track whether FioCruz, GE Healthcare, Caliber and other collaborators advance programs or generate license, milestone or royalty revenue.
- Assess clinical and regulatory progress beyond the completed H1N1 and H5N1 Phase 1 studies, particularly for C1 esterase inhibitor, yellow fever, malaria, hookworm and biodefense candidates.
- Evaluate future dilution from approximately 25.4 million warrants, 6.8 million options and potential additional equity financing.
- Confirm the company’s NYSE MKT listing status and subsequent compliance actions.
- Monitor whether cash resources remain sufficient, given the disclosed expectation that June 30, 2013 cash would fund operations only through the third quarter of fiscal 2014.